Physiologically Based Pharmacokinetic (PBPK) modeling in children

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 1, 2012, Pages 40-49

  Barrett, J S ^a   Della Casa Alberighi, O ^b   Laer S ^c   Meibohm, B ^d  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b G GASLINI INSTITUTE   (Italy)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DEVELOPMENT; HUMAN; MODEL; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSIOLOGICALLY BASED PHARMACOKINETIC; PRIORITY JOURNAL; REVIEW;

BIOMEDICAL RESEARCH; CHILD; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DRUG APPROVAL; HUMANS; MODELS, BIOLOGICAL; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGICAL PROCESSES; PHARMACOLOGY, CLINICAL; RISK ASSESSMENT;

EID: 84862617981     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.64     Document Type: Review

References (75)

1. Klassen, T.P., Hartling, L., Hamm, M., van der Lee, J.H., Ursum, J. & Offringa, M. StaR Child Health: an initiative for RCTs in children. Lancet 374, 1310-1312 (2009).
2. Johnson, T.N. The problems in scaling adult drug doses to children. Arch. Dis. Child. 93, 207-211 (2008).
3. European Medicines Agency. ICH Topic E11: Note for Guidance on Clinical Investigation of Medicinal Products in the Paediatric Population (CPMP/ICH/2711/99) 〈http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500002926.pdf〉. (Accessed 12 December 2011).
4. Lack, J.A. & Stuart-Taylor, M.E. Calculation of drug dosage and body surface area of children. Br. J. Anaesth. 78, 601-605 (1997).
5. Kearns, G.L., Abdel-Rahman, S.M., Alander, S.W., Blowey, D.L., Leeder, J.S. &Kauffman, R.E. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157-1167 (2003).
6. Läer, S., Barrett, J.S. & Meibohm, B. The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J. Clin. Pharmacol. 49, 889-904 (2009).
7. Bellanti, F. & Della Pasqua, O. Modelling and simulation as research tools in paediatric drug development. Eur. J. Clin. Pharmacol. 67 (suppl. 1), 75-86 (2011).
8. Manolis, E. & Pons, G. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. Br. J. Clin. Pharmacol. 68, 493-501 (2009).
9. Jadhav, P.R. & Kern, S.E. The need for modeling and simulation to design clinical investigations in children. J. Clin. Pharmacol. 50, 121S-129S (2010).
10. Manolis, E. et al. Role of modeling and simulation in pediatric investigation plans. Paediatr. Anaesth. 21, 214-221 (2011).
11. Björkman, S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br. J. Clin. Pharmacol. 59, 691-704 (2005).
12. Mouksassi, M.S., Marier, J.F., Cyran, J. & Vinks, A.A. Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome. Clin. Pharmacol. Ther. 86, 667-671 (2009).
13. Meibohm, B., Läer, S., Panetta, J.C. & Barrett, J.S. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 7, E475-E487 (2005).
14. Läer, S. et al. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J. Am. Coll. Cardiol. 46, 1322-1330 (2005).
15. Poulin, P. et al. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J. Pharm. Sci. 100, 4127-4157 (2011).
16. Rowland, M., Peck, C. & Tucker, G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51, 45-73 (2011).
17. Edginton, A.N., Schmitt, W., Voith, B. & Willmann, S. A mechanistic approach for the scaling of clearance in children. Clin. Pharmacokinet. 45, 683-704 (2006).
18. Bartelink, I.H., Rademaker, C.M., Schobben, A.F. & van den Anker, J.N. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin. Pharmacokinet. 45, 1077-1097 (2006).
19. Cella, M., Gorter de Vries, F., Burger, D., Danhof, M. & Della Pasqua, O. A model-based approach to dose selection in early pediatric development. Clin. Pharmacol. Ther. 87, 294-302 (2010).
20. Edginton, A.N., Schmitt, W. & Willmann, S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin. Pharmacokinet. 45, 1013-1034 (2006).
21. Aarons, L. Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. Br. J. Clin. Pharmacol. 60, 581-583 (2005).
22. Lowe, P.J., Hijazi, Y., Luttringer, O., Yin, H., Sarangapani, R. & Howard, D. On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica. 37, 1331-1354 (2007).
23. Jamei, M., Dickinson, G.L. & Rostami-Hodjegan, A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down'recognition of covariates. Drug Metab. Pharmacokinet. 24, 53-75 (2009).
24. Alcorn, J. & McNamara, P.J. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin. Pharmacokinet. 41, 959-998 (2002).
25. Johnson, T.N., Rostami-Hodjegan, A. & Tucker, G.T. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 45, 931-956 (2006).
26. Johnson, T.N., Tucker, G.T., Tanner, M.S. & Rostami-Hodjegan, A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl. 11, 1481-1493 (2005).
27. Ginsberg, G., Hattis, D., Russ, A. & Sonawane, B. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents. J. Toxicol. Environ. Health Part A 67, 297-329 (2004).
28. Edginton, A.N. & Willmann, S. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin. Pharmacokinet. 47, 743-752 (2008).
29. Hurtt, M.E. et al. Juvenile animal studies: testing strategies and design. Birth Defects Res. B Dev. Reprod. Toxicol. 71, 281-288 (2004).
30. US Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for Industry: Nonclinical Safety Evaluation of Pediatric Drug Products, February 2006 〈http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm079247.pdf〉. Accessed 16 December 2011.
31. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the need for non-clinical testing in juvenile animals of pharmaceuticals for paediatric indications (CHMP/SWP/169215/05), August 2008 〈http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2009/09/WC500003305.pdf〉. Accessed 12 December 2011.
32. Parrott, N. et al. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin. Pharmacokinet. 50, 613-623 (2011).
33. Baldrick, P. Juvenile animal testing in drug development - is it useful? Regul. Toxicol. Pharmacol. 57, 291-299 (2010).
34. Zhang, F. et al. Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab. Dispos. 39, 15-21 (2011).
35. Bradshaw-Pierce, E.L., Eckhardt, S.G. & Gustafson, D.L. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin. Cancer Res. 13, 2768-2776 (2007).
36. Horrobin, D.F. Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nat. Rev. Drug Discov. 2, 151-154 (2003).
37. Kamb, A. What's wrong with our cancer models? Nat. Rev. Drug Discov. 4, 161-165 (2005).
38. Danhof, M., de Lange, E.C., Della Pasqua, O.E., Ploeger, B.A. & Voskuyl, R.A. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol. Sci. 29, 186-191 (2008).
39. Timchalk, C., Kousba, A.A. & Poet, T.S. An age-dependent physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus insecticide chlorpyrifos in the preweanling rat. Toxicol. Sci. 98, 348-365 (2007).
40. Burghaus, R. et al. Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation. PLoS ONE 6, e17626 (2011).
41. Edginton, A.N., Schmitt, W. & Willmann, S. Application of physiology-based pharmacokinetic and pharmacodynamic modeling to individualized target-controlled propofol infusions. Adv. Ther. 23, 143-158 (2006).
42. Johnson, M. et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats. Pharm. Res. 28, 2490-2504 (2011).
43. Blesch, K.S., Gieschke, R., Tsukamoto, Y., Reigner, B.G., Burger, H.U. & Steimer, J.L. Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience. Invest. New Drugs 21, 195-223 (2003).
44. Yim, D.S., Zhou, H., Buckwalter, M., Nestorov, I., Peck, C.C. & Lee, H. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J. Clin. Pharmacol. 45, 246-256 (2005).
45. rd. Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul. Toxicol. Pharmacol. 38, 1-16 (2003).
46. Pelekis, M., Gephart, L.A. & Lerman, S.E. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds. Regul. Toxicol. Pharmacol. 33, 12-20 (2001).
47. Price, K., Haddad, S. & Krishnan, K. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J. Toxicol. Environ. Health Part A 66, 417-433 (2003).
48. DeWoskin, R.S. & Thompson, C.M. Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants. Regul. Toxicol. Pharmacol. 51, 66-86 (2008).
49. Edginton, A.N. Knowledge-driven approaches for the guidance of first-in-children dosing. Paediatr. Anaesth. 21, 206-213 (2011).
50. Johnson, T.N. & Rostami-Hodjegan, A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr. Anaesth. 21, 291-301 (2011).
51. Baber, N.S. Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children? Br. J. Clin. Pharmacol. 59, 660-662 (2005).
52. Reigner, B.G. & Blesch, K.S. Estimating the starting dose for entry into humans: principles and practice. Eur. J. Clin. Pharmacol. 57, 835-845 (2002).
53. Muller, P.Y., Milton, M., Lloyd, P., Sims, J. & Brennan, F.R. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr. Opin. Biotechnol. 20, 722-729 (2009).
54. Rocchetti, M., Simeoni, M., Pesenti, E., De Nicolao, G. & Poggesi, I. Predicting the active doses in humans from animal studies: a novel approach in oncology. Eur. J. Cancer 43, 1862-1868 (2007).
55. Tod, M., Jullien, V. & Pons, G. Facilitation of drug evaluation in children by population methods and modelling. Clin. Pharmacokinet. 47, 231-243 (2008).
56. Berry, L.M., Roberts, J., Be, X., Zhao, Z. & Lin, M.H. Prediction of V(ss) from in vitro tissue-binding studies. Drug Metab. Dispos. 38, 115-121 (2010).
57. Holford, N.H., Kimko, H.C., Monteleone, J.P. & Peck, C.C. Simulation of clinical trials. Annu. Rev. Pharmacol. Toxicol. 40, 209-234 (2000).
58. Barrett, JS. Modeling and simulation in pediatric research and development. In Clinical Trial Simulations: Applications & Trends (eds. Kimko, H. & Peck, C.), 401-433 (Springer Science + Business Media, New York, 2011).
59. Derendorf, H. & Meibohm, B. Modeling of pharmacokinetic/ pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm. Res. 16, 176-185 (1999).
60. Lowe, P.J., Tannenbaum, S., Wu, K., Lloyd, P. & Sims, J. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin. Pharmacol. Toxicol. 106, 195-209 (2010).
61. Stephenson, T. How children's responses to drugs differ from adults. Br. J. Clin. Pharmacol. 59, 670-673 (2005).
62. Anderson, B.J. & Larsson, P. A maturation model for midazolam clearance. Paediatr. Anaesth. 21, 302-308 (2011).
63. Price, P.S. et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 33, 469-503 (2003).
64. Willmann, S. et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J. Pharmacokinet. Pharmacodyn. 34, 401-431 (2007).
65. Barrett, J. et al. Model-based Drug Development for Oncology Agents. Exp. Opin. Drug Discov. 2, 185-209 (2007).
66. Steimer, J.L. et al. Modelling the genesis and treatment of cancer: the potential role of physiologically based pharmacodynamics. Eur. J. Cancer 46, 21-32 (2010).
67. Bruckner, J.V. Differences in sensitivity of children and adults to chemical toxicity: the NAS panel report. Regul. Toxicol. Pharmacol. 31, 280-285 (2000).
68. de Zwart, L.L., Haenen, H.E., Versantvoort, C.H., Wolterink, G., van Engelen, J.G. & Sips, A.J. Role of biokinetics in risk assessment of drugs and chemicals in children. Regul. Toxicol. Pharmacol. 39, 282-309 (2004).
69. Stone, K.D. Atopic diseases of childhood. Curr. Opin. Pediatr. 15, 495-511 (2003).
70. Breitner, J.C. et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 72, 1899-1905 (2009).
71. Johnson, T.N. & Thomson, M. Intestinal metabolism and transport of drugs in children: the effects of age and disease. J. Pediatr. Gastroenterol. Nutr. 47, 3-10 (2008).
72. Hoppu, K. Can we get the necessary clinical trials in children and avoid the unnecessary ones? Eur. J. Clin. Pharmacol. 65, 747-748 (2009).
73. Khalil, F. & Läer, S. Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development. J. Biomed. Biotechnol. 90, 74-61 (2011).
74. Zhao, P. et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89, 259-267 (2011).
75. Huang, S.M. & Rowland, M. The role of physiologically based pharmacokinetic modeling in regulatory review. Clin. Pharmacol. Ther. 91, 542-549 (2012).